Immune cells: potential carriers or agents for drug delivery to the central nervous system
Abstract Drug delivery systems (DDS) have recently emerged as a promising approach for the unique advantages of drug protection and targeted delivery. However, the access of nanoparticles/drugs to the central nervous system (CNS) remains a challenge mainly due to the obstruction from brain barriers. Immune cells infiltrating the CNS in the pathological state have inspired the development of strategies for CNS foundation drug delivery. Herein, we outline the three major brain barriers in the CNS and the mechanisms by which immune cells migrate across the blood–brain barrier. We subsequently review biomimetic strategies utilizing immune cell-based nanoparticles for the delivery of nanoparticles/drugs to the CNS, as well as recent progress in rationally engineering immune cell-based DDS for CNS diseases. Finally, we discuss the challenges and opportunities of immune cell-based DDS in CNS diseases to promote their clinical development..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Military medical research - 11(2024), 1 vom: 29. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Shan-Shan [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Blood–brain barrier |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s40779-024-00521-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055342930 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055342930 | ||
| 003 | DE-627 | ||
| 005 | 20240329064711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40779-024-00521-y |2 doi | |
| 035 | |a (DE-627)SPR055342930 | ||
| 035 | |a (SPR)s40779-024-00521-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Zhang, Shan-Shan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune cells: potential carriers or agents for drug delivery to the central nervous system |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Abstract Drug delivery systems (DDS) have recently emerged as a promising approach for the unique advantages of drug protection and targeted delivery. However, the access of nanoparticles/drugs to the central nervous system (CNS) remains a challenge mainly due to the obstruction from brain barriers. Immune cells infiltrating the CNS in the pathological state have inspired the development of strategies for CNS foundation drug delivery. Herein, we outline the three major brain barriers in the CNS and the mechanisms by which immune cells migrate across the blood–brain barrier. We subsequently review biomimetic strategies utilizing immune cell-based nanoparticles for the delivery of nanoparticles/drugs to the CNS, as well as recent progress in rationally engineering immune cell-based DDS for CNS diseases. Finally, we discuss the challenges and opportunities of immune cell-based DDS in CNS diseases to promote their clinical development. | ||
| 650 | 4 | |a Drug delivery systems |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immune cells |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Blood–brain barrier |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Central nervous system |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Li, Ruo-Qi |4 aut | |
| 700 | 1 | |a Chen, Zhong |4 aut | |
| 700 | 1 | |a Wang, Xiao-Ying |4 aut | |
| 700 | 1 | |a Dumont, Aaron S. |4 aut | |
| 700 | 1 | |a Fan, Xiang |0 (orcid)0000-0001-7697-0378 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Military medical research |d BioMed Central, 2014 |g 11(2024), 1 vom: 29. März |w (DE-627)SPR03774027X |w (DE-600)2768940-2 |x 2054-9369 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:1 |g day:29 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40779-024-00521-y |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 1 |b 29 |c 03 | ||